STRATEGIC SCIENTIFIC EVALUATION · CONTINUUM INNOVATIVE
Strategic Scientific Evaluation.Helping organizations make better scientific decisions before they become expensive commercial decisions.
- 30 yrs
- Sustained research
- 30+
- Peer-reviewed publications
- 25
- Countries commercialized
- $100M+
- Lifetime product revenue
The method
The Continuum Translational Assessment Framework™
Every Continuum evaluation follows one published structure — biological plausibility, mechanistic evidence, quality of experimental evidence, translational feasibility, commercial differentiation, IP defensibility, regulatory complexity, investment risk, and an overall recommendation. Nine dimensions, assessed in the same order, ending in a written verdict.
What do people pay me to be right about?
Not what I do. Not what I have published. Not what I have patented. What organizations have actually paid me for, across three decades, is a narrower and more valuable thing: evaluating complex biology and translating it into commercially intelligent decisions.
That is the whole practice. Hair biology is where I proved it — peer-reviewed mechanism work, transcriptomic analysis, issued and provisional intellectual property, and products commercialized onto pharmacy shelves across three continents. But hair is the evidence of the capability, not the boundary of it.
The question behind the question
A founder rarely searches for "due diligence." They search for some version of am I about to waste half a million dollars? That is the question this practice exists to answer plainly.
Judgment, not deliverables
Mechanistic literature is abundant and free. What is scarce is someone who will look at your data and say, on the record, this is solid — or stop.
Risk reduction, not consulting
The value is not a report. It is the two million dollars you did not spend pursuing a mechanism that could not have worked.
The questions this practice is built to answer
These are founders’ real questions, in founders’ real language. Each becomes a written evaluation as this section is built out — depth first, one at a time, rather than forty thin pages.
Every one of these pages ends the same way — with a section titled “What is the decision?” Given the available evidence, here is how I would advise a client. If it were my money, here is what I would do.
A platform, not a specialty
Evaluation is the capability. The verticals are where it is applied — and the architecture is deliberately built so that new verticals can be added without rebuilding the foundation.
Hair & skin actives
Where the capability was proven. Mechanism, formulation, claim defensibility, and commercial translation.
Regenerative medicine
Cell- and matrix-based approaches where the biology is plausible and the evidence is frequently not.
Formulation science
Why technically correct actives fail in finished goods — delivery, stability, exposure, and dose reality.
Longevity & healthspan
A field with extraordinary capital inflow and highly variable evidentiary discipline.
Where the evidence lives
An evaluation is only as credible as the person writing it. The underlying scientific record is public and checkable.
Research & publications
Peer-reviewed mechanism work, clinical protocol design, and transcriptomic analysis.
Intellectual property
Senescence biology, intracrine dynamics, autoimmune privilege, multi-nodal stabilization.
Commercial translation
Products taken from mechanism to on-shelf placement with Boots and regional pharmacy leaders — proof the translation step is not theoretical.
Decision frameworks
Written evaluations, published in full. Each answers one decision question end to end and closes with an explicit recommendation rather than a summary.
Evaluation note 01
Before you license an ingredient
Seven tests, in the order they should be run — mechanism, deliverable concentration, trial design, IP scope, claim substantiation, effect size, and prior passes.
Advisory
Typical engagements
Fractional Chief Scientific Officer, technology evaluation, scientific due diligence, mechanism review, and commercial strategy.
Credentials
Strategic partnership brief
The condensed record — research, intellectual property, and commercial translation across the GCC pharmacy network.
Questions decision-makers ask
The questions asked most often before an evaluation begins, answered plainly.
What is strategic scientific evaluation?
Strategic scientific evaluation is the independent assessment of whether a scientific asset — an ingredient, mechanism, patent, formulation, or clinical dataset — will hold up under commercial and regulatory pressure. It answers a decision question, not a research question: proceed, renegotiate, restructure, or stop.
How is an evaluation different from a consulting engagement?
Consulting produces deliverables. An evaluation produces a judgment. The output is a written position on whether the science supports the decision being contemplated, what would have to be true for it to work, and what evidence is missing — signed by the person who formed it.
When is the right time to commission an evaluation?
Before capital is committed: before a licence is signed, before a further development tranche is released, before a claim is taken to market, and before a data room is opened to a sophisticated acquirer. Evaluation after the wire transfer is forensics, not diligence.
Who performs the evaluation?
Evaluations are performed personally by Geno Marcovici, Ph.D., DABAAHP, Founder and Chief Scientific Officer of Continuum Innovative, LLC — author of peer-reviewed clinical and mechanistic research on follicular biology, holder of five intellectual-property programmes, and the developer of products commercialized through Boots Middle East and the leading GCC pharmacy retailers.
Which scientific fields are covered?
Hair and skin actives, regenerative medicine, formulation and delivery science, and longevity and healthspan — fields that share the same failure mode: mechanistically attractive science that cannot survive delivery, dose reality, trial design, or claim substantiation.
What does an evaluation actually reduce?
Risk of the expensive kind: licensing an asset whose effect size cannot support a price, funding a programme whose endpoint was chosen to survive scrutiny rather than detect effect, or building a brand on a claim that cannot be substantiated in the intended market.
Enquiries
Before it becomes an expensive commercial decision
Evaluation enquiries are read personally by Dr. Marcovici. If you are weighing a technology, a licence, a formulation, or a further tranche of spend, describe the decision in a paragraph — that is usually enough to tell whether an evaluation is worth either of our time.